Alteogen, "We Want to Discuss Possibilities Rather Than Limits" Stock Price 228,100 KRW (0.57%)

Alteogen is trading at 228,100 KRW as of 9:30 AM on the 29th, up 0.57% from the previous day. The trading volume is 33,622 shares, which is about 12.08% of the previous day's volume. Alteogen is known as a biosimilar developer.

On May 28, Lee Dong-geon, a researcher at Shinhan Financial Investment, stated, "The value of subcutaneous injection formulation drugs is highlighted along with the scalability of the Hybrozyme contract. The only companies possessing related platform technology are Alteogen and Halozyme. In particular, Alteogen, which grants non-exclusive rights, has limitless scalability compared to Halozyme, which grants exclusive rights. Attention should also be paid to the possibility of additional contracts with the same company. If a contract is signed with Keytruda, which has obtained approval for multiple indications, it is possible to have multiple contracts with the same company rather than a one-time deal." He set Alteogen's target price at 260,000 KRW.

Over the past five days, individual investors have net purchased 43,771 shares of Alteogen, while foreigners and institutions have net purchased 7,889 shares and net sold 55,161 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.